These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21965780)

  • 21. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
    Kim KP; Kim HS; Sym SJ; Bae KS; Hong YS; Chang HM; Lee JL; Kang YK; Lee JS; Shin JG; Kim TW
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1609-17. PubMed ID: 23595344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab.
    Ettlinger DE; Mitterhauser M; Wadsak W; Ostermann E; Farkouh A; Schueller J; Czejka M
    Anticancer Res; 2006; 26(2B):1337-41. PubMed ID: 16619542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.
    Rivory LP; Robert J
    Cancer Chemother Pharmacol; 1995; 36(2):176-9. PubMed ID: 7767955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
    Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
    Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
    Escoriaza J; Aldaz A; Castellanos C; Calvo E; Giráldez J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):159-68. PubMed ID: 10821401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies.
    Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
    Talanta; 2008 Sep; 76(5):1015-21. PubMed ID: 18761148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.
    Tobin PJ; Beale P; Noney L; Liddell S; Rivory LP; Clarke S
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):309-16. PubMed ID: 16003560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.
    Hamada A; Aoki A; Terazaki H; Ito K; Yokoo K; Sasaki Y; Saito H
    Ther Drug Monit; 2005 Aug; 27(4):536-8. PubMed ID: 16044114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy.
    Hofmann C; Buttenschoen K; Straeter J; Henne-Bruns D; Kornmann M
    Anticancer Res; 2005; 25(2A):795-804. PubMed ID: 15868911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
    Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P
    J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.
    Lokiec F; Canal P; Gay C; Chatelut E; Armand JP; Roché H; Bugat R; Gonçalvès E; Mathieu-Boué A
    Cancer Chemother Pharmacol; 1995; 36(1):79-82. PubMed ID: 7720181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intermittent hepatic arterial infusion with systemic chemotherapy for metastatic colorectal cancer].
    Ide Y; Mikami K; Murata K
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2172-4. PubMed ID: 20037360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
    Mathijssen RH; Verweij J; de Jonge MJ; Nooter K; Stoter G; Sparreboom A
    J Clin Oncol; 2002 Jan; 20(1):81-7. PubMed ID: 11773157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
    Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
    Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
    J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited potential of hepatic arterial infusion of irinotecan.
    De Jong FA; Mathijssen RH; Verweij J
    J Chemother; 2004 Nov; 16 Suppl 5():48-50. PubMed ID: 15675478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
    Koizumi T; Kubo K; Hanaoka M; Miyahara T; Kaneki T; Yamamoto H; Ge RL; Fujimoto K; Kobayashi T; Sekiguchi M
    Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.